Published in Cell on November 04, 2005
The epigenomics of cancer. Cell (2007) 30.91
Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol (2010) 8.55
Recent progress in the biology and physiology of sirtuins. Nature (2009) 7.73
Sirtuins in mammals: insights into their biological function. Biochem J (2007) 7.60
Telomere dysfunction induces metabolic and mitochondrial compromise. Nature (2011) 6.36
miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A (2008) 6.24
Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol Cell (2007) 5.29
Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell (2008) 5.11
Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol (2012) 4.86
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One (2008) 4.32
Negative regulation of the deacetylase SIRT1 by DBC1. Nature (2008) 4.29
Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet (2006) 3.54
Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell (2008) 3.32
How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer (2008) 3.17
Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell (2012) 2.96
Metabolism and cancer: the circadian clock connection. Nat Rev Cancer (2009) 2.91
SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci (2009) 2.80
p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med (2010) 2.54
SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat Cell Biol (2007) 2.47
SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol Cell (2007) 2.42
Sirtuins mediate mammalian metabolic responses to nutrient availability. Nat Rev Endocrinol (2012) 2.12
Retracted Metabolic regulation of SIRT1 transcription via a HIC1:CtBP corepressor complex. Proc Natl Acad Sci U S A (2007) 2.09
Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev (2012) 1.99
miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem (2011) 1.98
Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest (2010) 1.97
Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys (2010) 1.91
The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci U S A (2011) 1.90
Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)? Pharmacol Rev (2011) 1.85
Energy balance, host-related factors, and cancer progression. J Clin Oncol (2010) 1.85
An acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity. Mol Cell Biol (2007) 1.69
SIRT1 acts as a nutrient-sensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity. Mol Biol Cell (2008) 1.66
Colorectal cancer: a model for epigenetic tumorigenesis. Gut (2006) 1.62
SIRT6 in DNA repair, metabolism and ageing. J Intern Med (2008) 1.61
Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene (2011) 1.60
Retracted Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control. Oncogene (2008) 1.59
The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther (2013) 1.57
Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood (2011) 1.52
Sorting out functions of sirtuins in cancer. Oncogene (2013) 1.47
SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta (2010) 1.46
The dual role of sirtuins in cancer. Genes Cancer (2011) 1.45
Calorie restriction and the exercise of chromatin. Genes Dev (2009) 1.44
CK2 is the regulator of SIRT1 substrate-binding affinity, deacetylase activity and cellular response to DNA-damage. PLoS One (2009) 1.43
Janus-faced role of SIRT1 in tumorigenesis. Ann N Y Acad Sci (2012) 1.43
Retracted HIC1 regulates tumor cell responses to endocrine therapies. Mol Endocrinol (2009) 1.42
Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma. Genes Dev (2008) 1.42
HIC1 attenuates Wnt signaling by recruitment of TCF-4 and beta-catenin to the nuclear bodies. EMBO J (2006) 1.41
SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet (2011) 1.41
Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity. PLoS One (2008) 1.41
Sirtuins at a glance. J Cell Sci (2011) 1.41
SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions. Biochim Biophys Acta (2009) 1.41
Airway epithelial stem cells and the pathophysiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc (2006) 1.34
SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem (2009) 1.33
SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol Cancer Res (2008) 1.30
Comparing and contrasting the roles of AMPK and SIRT1 in metabolic tissues. Cell Cycle (2008) 1.28
FoxO1 mediates an autofeedback loop regulating SIRT1 expression. J Biol Chem (2010) 1.27
Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients. Neoplasia (2009) 1.25
DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer (2015) 1.25
Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci (2010) 1.24
Regulation of SIRT1 activity by genotoxic stress. Genes Dev (2012) 1.22
SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancer. Cancer Res (2011) 1.21
SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol (2009) 1.19
SIRT1 regulates Dishevelled proteins and promotes transient and constitutive Wnt signaling. Proc Natl Acad Sci U S A (2010) 1.19
A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53. EMBO Mol Med (2012) 1.18
Methyltransferase Set7/9 regulates p53 activity by interacting with Sirtuin 1 (SIRT1). Proc Natl Acad Sci U S A (2011) 1.17
Redox regulation of SIRT1 in inflammation and cellular senescence. Free Radic Biol Med (2013) 1.17
The role of mammalian sirtuins in the regulation of metabolism, aging, and longevity. Handb Exp Pharmacol (2011) 1.16
Biochemical effects of SIRT1 activators. Biochim Biophys Acta (2009) 1.16
Sirtuins and their relevance to the kidney. J Am Soc Nephrol (2010) 1.15
SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells. Oncogene (2012) 1.15
Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol (2011) 1.14
SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLoS One (2012) 1.13
HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors. Int J Biochem Cell Biol (2008) 1.13
Differential regulation of HIC1 target genes by CtBP and NuRD, via an acetylation/SUMOylation switch, in quiescent versus proliferating cells. Mol Cell Biol (2010) 1.11
A biotin switch-based proteomics approach identifies 14-3-3ζ as a target of Sirt1 in the metabolic regulation of caspase-2. Mol Cell (2011) 1.09
Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth. Cancer Biol Ther (2012) 1.09
HIPK2 modulates p53 activity towards pro-apoptotic transcription. Mol Cancer (2009) 1.08
Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy. Blood (2010) 1.07
The ways and means that fine tune Sirt1 activity. Trends Biochem Sci (2013) 1.07
The intersection between DNA damage response and cell death pathways. Exp Oncol (2012) 1.06
hSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in response to DNA damage. Mol Cell Biol (2009) 1.06
A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1. Oncogene (2010) 1.06
The Roles of SIRT1 in Cancer. Genes Cancer (2013) 1.04
The multifaceted functions of sirtuins in cancer. Nat Rev Cancer (2015) 1.04
Sirtuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription. J Biomed Biotechnol (2011) 1.03
From 'omics' to complex disease: a systems biology approach to gene-environment interactions in cancer. Cancer Cell Int (2010) 1.02
Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res (2010) 1.02
Structure, function and regulation of CSB: a multi-talented gymnast. Mech Ageing Dev (2013) 1.02
Role of DNA methylation in renal cell carcinoma. J Hematol Oncol (2015) 1.02
Scavenger chemokine (CXC motif) receptor 7 (CXCR7) is a direct target gene of HIC1 (hypermethylated in cancer 1). J Biol Chem (2009) 1.01
The REGγ proteasome regulates hepatic lipid metabolism through inhibition of autophagy. Cell Metab (2013) 1.01
Expression of SIRT1 and DBC1 is associated with poor prognosis of soft tissue sarcomas. PLoS One (2013) 1.01
Calorie restriction and cancer prevention: a mechanistic perspective. Cancer Metab (2013) 1.01
Protein deacetylation by sirtuins: delineating a post-translational regulatory program responsive to nutrient and redox stressors. Cell Mol Life Sci (2010) 1.00
High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients. BMC Cancer (2014) 0.98
Sirtuin inhibitors as anticancer agents. Future Med Chem (2014) 0.98
Enterocyte-specific inactivation of SIRT1 reduces tumor load in the APC(+/min) mouse model. PLoS One (2013) 0.98
Cytoplasmic Kaiso is associated with poor prognosis in non-small cell lung cancer. BMC Cancer (2009) 0.98
Emerging Roles of SIRT1 in Cancer Drug Resistance. Genes Cancer (2013) 0.97
POZ/BTB and AT-hook-containing zinc finger protein 1 (PATZ1) inhibits endothelial cell senescence through a p53 dependent pathway. Cell Death Differ (2011) 0.97
Expression of SIRT1 and DBC1 in Gastric Adenocarcinoma. Korean J Pathol (2012) 0.96
The epigenomics of cancer. Cell (2007) 30.91
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Modes of p53 regulation. Cell (2009) 9.31
Mammalian SIRT1 represses forkhead transcription factors. Cell (2004) 8.89
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature (2002) 7.71
Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature (2003) 6.07
DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med (2008) 5.87
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Acetylation is indispensable for p53 activation. Cell (2008) 5.70
Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell (2006) 5.64
p53 ubiquitination: Mdm2 and beyond. Mol Cell (2006) 5.57
Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol (2003) 5.46
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet (2002) 5.38
SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell (2007) 5.30
Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science (2003) 5.23
Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell (2012) 4.96
SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab (2008) 4.89
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell (2005) 4.60
Non-transcriptional control of DNA replication by c-Myc. Nature (2007) 4.55
Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell (2002) 4.33
Negative regulation of the deacetylase SIRT1 by DBC1. Nature (2008) 4.29
FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab (2005) 4.14
A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell (2004) 4.05
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell (2012) 3.82
Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nat Genet (2005) 3.66
Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res (2006) 3.59
Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet (2006) 3.54
Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells (2010) 3.53
The cancer epigenome--components and functional correlates. Genes Dev (2006) 3.40
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem (2002) 3.37
How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer (2008) 3.17
Non-invasive prenatal measurement of the fetal genome. Nature (2012) 3.11
Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol Cell Proteomics (2007) 3.09
Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell (2011) 3.07
Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci U S A (2004) 3.06
Parc: a cytoplasmic anchor for p53. Cell (2003) 3.06
Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res (2006) 3.05
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Acetylation inactivates the transcriptional repressor BCL6. Nat Genet (2002) 3.00
PcG proteins, DNA methylation, and gene repression by chromatin looping. PLoS Biol (2008) 2.85
Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol (2006) 2.85
Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res (2002) 2.84
Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol (2005) 2.72
A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol (2005) 2.64
SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J Biol Chem (2005) 2.59
Stem cell chromatin patterns: an instructive mechanism for DNA hypermethylation? Cell Cycle (2007) 2.55
Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet (2008) 2.55
p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med (2010) 2.54
Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ. Cell (2012) 2.46
GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol (2003) 2.42
Hematopoietic stem cells convert into liver cells within days without fusion. Nat Cell Biol (2004) 2.41
Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst (2002) 2.38
Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell (2003) 2.38
Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway. PLoS Biol (2006) 2.35
Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med (2011) 2.33
Nearly finished genomes produced using gel microdroplet culturing reveal substantial intraspecies genomic diversity within the human microbiome. Genome Res (2013) 2.29
Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res (2003) 2.28
Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res (2008) 2.16
Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci U S A (2007) 2.11
A novel 6C assay uncovers Polycomb-mediated higher order chromatin conformations. Genome Res (2008) 2.10
A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J Infect Dis (2005) 2.09
Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res (2011) 2.06
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood (2006) 2.06
Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res (2003) 2.04
Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res (2003) 2.03
Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res (2003) 2.03
Microfluidics for flow cytometric analysis of cells and particles. Physiol Meas (2005) 2.00
Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut (2012) 2.00
DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2. Cancer Res (2007) 1.96
Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res (2004) 1.93
Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem (2003) 1.92
A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res (2012) 1.92
Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol (2006) 1.91
Cancer epigenetics: linking basic biology to clinical medicine. Cell Res (2011) 1.88
Phosphorylation of Tip60 by GSK-3 determines the induction of PUMA and apoptosis by p53. Mol Cell (2011) 1.87
Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res (2009) 1.87
SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice. J Clin Invest (2012) 1.82
Defining a gene promoter methylation signature in sputum for lung cancer risk assessment. Clin Cancer Res (2012) 1.80
Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res (2009) 1.80
The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev (2005) 1.79
GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res (2009) 1.78
Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet (2003) 1.77
Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J Biol Chem (2005) 1.77
hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res (2007) 1.77
SnapShot: p53 posttranslational modifications. Cell (2008) 1.75